Drug Profile

CBG 131

Alternative Names: CBG-131

Latest Information Update: 27 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Carbiogene Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

11 Feb 2026 Preclinical trials in Gastric cancer in China (IV) prior to February 2026
11 Feb 2026 Preclinical trials in Pancreatic cancer in China (IV) prior to February 2026
06 Feb 2026 Carbiogene Therapeutics plans a phase I trial for Gastric cancer (Late-stage disease, Second-line therapy or greater) and Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT07394205)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com